SMARCA4 and neoplasm: PFI‐3 was developed as a highly selective small molecule bromodomain inhibitor of the BRG1 and BRM subunits of the SWI/SNF complex, which has minimal ‘off‐target’ effects in primary human cells and no evidence of toxicity on the NCI‐60 panel of tumour cell lines.18, 19